As senior executives of and investors in numerous growth oriented and entrepreneurial healthcare companies across the country dealing with hospitals, doctors, clinical services providers, device and pharma companies, insurers and most importantly patients, we are well aware of the pandemic’s impact on those most affected by COVID-19. The U.S. healthcare system is the most innovative and technologically advanced in the world, but it is also fragmented geographically and highly regulated, which presented obstacles to an efficient, nationwide coordinated response to the COVID-19 crisis. At the outset of the outbreak, it was necessary to prohibit all but emergency healthcare services, including elective surgeries and other clinical care to repurpose capacity for COVID-19 cases. The industry quickly mobilized towards this goal in extraordinary ways, and all Americans have been humbled by the commitment and performance of our frontline healthcare workers. However, this dramatic reduction in overall capacity endangered the very healthcare system that the stay-at-home orders are/were intended to protect, causing unintended consequences to all types of patients…